BCI
APLS

Brinker Capital Investments’s Apellis Pharmaceuticals APLS Stock Holding History

Brinker Capital Investments’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,899
Closed -$237K – 1875
2026
Q1 		$237K Buy
+5,899
New +$127K ﹤0.01% 1775
2024
Q4 		– Sell
-31,418
Closed -$906K – 1822
2024
Q3 		$906K Sell
31,418
-4,914
-14% -$182K 0.01% 1094
2024
Q2 		$1.39M Buy
36,332
+9,253
+34% +$419K 0.01% 820
2024
Q1 		$1.59M Buy
27,079
+7,330
+37% +$467K 0.02% 768
2023
Q4 		$1.35M Sell
19,749
-7,647
-28% -$388K 0.02% 812
2023
Q3 		$1.04M Buy
27,396
+10,713
+64% +$471K 0.01% 916
2023
Q2 		$1.52M Sell
16,683
-642
-4% -$55.4K 0.02% 774
2023
Q1 		$1.14M Buy
+17,325
New +$1,000K 0.01% 817

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Brinker Capital Investments's APLS Position: Q2 2026 in Review

Brinker Capital Investments sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 5,899 shares — an estimated $237K sold.

Brinker Capital Investments first reported a position in APLS in Q1 2023 and held it in 8 quarters. The position peaked at $1.59M in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Brinker Capital Investments reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Brinker Capital Investments sold 5,899 Apellis Pharmaceuticals shares in Q2 2026, an estimated $237K.
  • Brinker Capital Investments first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 8 quarters.
  • Brinker Capital Investments's Apellis Pharmaceuticals position peaked at $1.59M in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.